Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 251-717-2 | CAS number: 33885-51-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 19 February - 17 August 2020
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Justification for type of information:
- At this time, studies in laboratory animals provide the best available basis for extrapolation to humans and are required to support regulatory submissions. Acceptable models which do not use live animals currently do not exist.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 020
- Report date:
- 2020
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- 2016
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: EPA OPPTS 870.3650, Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test
- Version / remarks:
- 2000
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 6,6-dimethylbicyclo[3.1.1]hept-2-ene-2-propionaldehyde
- EC Number:
- 251-717-2
- EC Name:
- 6,6-dimethylbicyclo[3.1.1]hept-2-ene-2-propionaldehyde
- Cas Number:
- 33885-51-7
- Molecular formula:
- C12H18O
- IUPAC Name:
- 3-(6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)propanal
- Test material form:
- liquid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Remarks:
- Crl: WI(Han)
- Details on species / strain selection:
- The Wistar Han rat was chosen as the animal model for this study as it is an accepted rodent species for toxicity testing by regulatory agencies. Charles River Den Bosch has general and reproduction/developmental historical data in this species from the same strain and source. This animal model has been proven to be susceptible to the effects of reproductive toxicants.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland, Sulzfeld, Germany
- Females nulliparous and non-pregnant: yes
- Age at study initiation: 10-11 weeks (males), 13-14 weeks (females)
- Weight at study initiation: 296 - 350 g (males), 195 and 249 g (females)
- Fasting period before study: No (except for males which were fasted overnight with a maximum of 24 hours before sacrifice; females were not fasted)
- Housing: On arrival and following the pretest (females only) and pre-mating period, animals were group housed (up to 5 animals of the same sex and same dosing group together) in polycarbonate cages (Macrolon, MIV type, height 18 cm). During the mating phase, males and females were cohabitated on a 1:1 basis in Macrolon plastic cages (MIII type, height 18 cm). During the post-mating phase, males were housed in their home cage (Macrolon plastic cages, MIV type, height 18 cm) with a maximum of 5 males/cage. Females were individually housed in Macrolon plastic cages (MIII type, height 18 cm). During the lactation phase, females were housed in Macrolon plastic cages (MIII type, height 18 cm). During locomotor activity monitoring, animals were housed individually in a Hi-temp polycarbonate cage (Ancare corp., USA; dimensions: 48.3 x 26.7 x 20.3 cm) without cage-enrichment, bedding material, food and water. The cages contained appropriate bedding.
- Diet: Pelleted rodent diet (SM R/M-Z from SSNIFF® Spezialdiäten GmbH, Soest, Germany), ad libitum)
- Water: Municipal tap water, ad libitum
- Acclimation period: 6 days (females), 7 days (males)
DETAILS OF FOOD AND WATER QUALITY:
The feed was analyzed by the supplier for nutritional components and environmental contaminants. Periodic analysis of the water was performed. It is considered that there were no known contaminants in the feed and in the water that would interfere with the objectives of the study.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-21
- Humidity (%): 45-56
- Air changes (per hr): 10 or more air changes per hour with 100% fresh air (no air recirculation)
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 05 March 2020 To: 01 May 2020
Administration / exposure
- Route of administration:
- oral: gavage
- Details on route of administration:
- The oral route of administration was selected because this route is expected to present the toxic effects best because full oral absorption is likely and route to route extrapolation is possible.
- Vehicle:
- unchanged (no vehicle)
- Remarks:
- Control animals received water.
- Details on oral exposure:
- The test item was administered as received. An adequate amount of the test item was dispensed into daily aliquots, which were stored the same as for the bulk test item until use. If practically possible, the dosing formulations and vehicle were continuously stirred until and during dosing.
Adjustment was made for specific gravity of the test item (0.9584 (D25/25)). No correction was made for the purity/composition of the test item.
The dose volume for each animal was based on the most recent body weight measurement. The doses were given using a plastic feeding tube. Dose volumes ≤ 50 µL were administered using a digital syringe and dose volumes > 50 µL were given with a plastic feeding tube connected to an appropriately graded syringe.
A dose control system was used as additional check to verify the dosing procedure according to Standard Operating Procedures.
Dose volumes were 0.0313, 0.0626, 0.125 mL/kg bw for the low, mid and high dose groups, respectively. The control animals received 0.125 mL water/ kg bw. - Analytical verification of doses or concentrations:
- no
- Details on analytical verification of doses or concentrations:
- The substance was dosed as such. Samples for dose formulation analysis were not collected.
- Duration of treatment / exposure:
- Males were treated for 2 weeks prior to mating, during mating, and up to termination (for 29 days). Females that delivered offspring were treated for 2 weeks prior to mating, during mating, during post-coitum, and at least 13 days of lactation (for 50-57 days). Females that failed to deliver pups were treated for 41-43 days.
- Frequency of treatment:
- Once daily, 7 days per week
Doses / concentrationsopen allclose all
- Dose / conc.:
- 30 mg/kg bw/day (actual dose received)
- Remarks:
- Low dose group
- Dose / conc.:
- 60 mg/kg bw/day (actual dose received)
- Remarks:
- Mid dose group
- Dose / conc.:
- 120 mg/kg bw/day (actual dose received)
- Remarks:
- High dose group
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
The dose levels were selected based on the results of a 14-day Dose Range Finder with oral administration of Pino Acetaldehyde in rats (Test Facility Reference No. 20137515) in which mortality was observed at 450 mg/kg bw/day but no severe effects were recorded at 90 mg/kg bw/day, and in an attempt to produce graded responses to the test item.
In the Dose Range Finder study significant treatment related changes were recorded for sperm parameters at 450 mg/kg bw/day (reduced mean motile sperm, mean progressive motility, mean number of cells with normal morphology and mean number of cells with coiled tail, and increased mean number of cells with detached head and mean number of cells with abnormal neck. Epididymal sperm count was not considered affected by treatment. These findings were not recorded at 90 mg/kg bw/day. - Positive control:
- No.
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily for general health/mortality and moribundity
- The circumstances of any death were recorded in detail.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: once daily
- During the dosing period, these observations were performed after dosing at no specific time point, but within a similar time period after dosing for the respective animals (no peak effect of occurrence of clinical signs was observed in the dose range finder)
- The time of onset, grade and duration of any observed sign was recorded. Signs were graded for severity.
- Clinical observations were conducted in a standard arena beginning before the first administration of the test item and then once weekly throughout treatment.
BODY WEIGHT: Yes
- Time schedule for examinations: Animals were weighed individually on the first day of treatment (prior to dosing), and weekly thereafter. Mated females were weighed on Days 0, 4, 7, 11, 14, 17, and 20 post-coitum and during lactation on PND 1, 4, 7, and 13.
The terminal weight was recorded on the day of scheduled necropsy.
FOOD CONSUMPTION: Yes
- Food consumption was quantitatively measured weekly, except for males and females which were housed together for mating and for females without evidence of mating. Food consumption of mated females was measured on Days 0, 4, 7, 11, 14, 17, and 20 post-coitum and during lactation on PND 1, 4, 7, and 13.
WATER CONSUMPTION: Yes
- Water consumption was monitored on regular basis throughout the study by visual inspection of the water bottles.
HAEMATOLOGY: Yes
- Time schedule for collection of blood: on the day of scheduled necropsy
- Anaesthetic used for blood collection: Yes (isoflurane)
- Animals fasted: Males were fasted overnight with a maximum of 24 hours before blood sampling, but water was available. Females were not fasted overnight.
- How many animals: 5/sex/group
- Parameters as specified in the OECD guideline were included (coagulation parameters (prothrombin time and activated partial thromboplastin time) were included.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: on the day of scheduled necropsy
- Anaesthetic used for blood collection: Yes (isoflurane)
- Animals fasted: Males were fasted overnight with a maximum of 24 hours before blood sampling, but water was available. Females were not fasted overnight.
- How many animals: 5/sex/group
- Parameters as specified in the OECD guideline were included
- Thyroid hormone level (total T4) was measured for males
FUNCTIONAL TESTS:
Functional tests were performed on 5 males/ group during Week 4 of treatment and 5 females/group during the last week of lactation (i.e. PND 6-13), These tests were performed after dosing, after completion of clinical observations (including arena observation, if applicable).
The following tests were performed:
- Hearing ability;
- Pupillary reflex;
- Static righting reflex;
- Fore- and hind-limb grip strength, recorded as the mean of three measurements per animal;
- Locomotor activity (recording period: 1-hour under normal laboratory light conditions, using a computerized monitoring system). Total movements and ambulations were reported. Ambulations represent movements characterized by a relocation of the entire body position like walking, whereas total movements represent all movements made by the animals, including ambulations but also smaller or more fine movements like grooming, weaving or movements of the head.
ESTROUS CYCLE DETERMINATION
- evaluated by examining the vaginal cytology of samples obtained by vaginal lavage. Daily vaginal lavage was performed for all females beginning 14 days prior to treatment (pretest period), the first 14 days of treatment and during mating until evidence of copulation was observed. Vaginal lavage was continued for those females with no evidence of copulation until termination of the mating period.
On the day of necropsy, a vaginal lavage was also taken to determine the stage of estrous. - Sacrifice and pathology:
- Necropsy was conducted for animals that died on study, and specified tissues were saved.
Animals surviving until scheduled euthanasia were weighed, and deeply anaesthetized using isoflurane and subsequently exsanguinated and subjected to a full post mortem examination. The numbers of former implantation sites were recorded for all paired females. In case no macroscopically visible implantation sites were present, non-gravid uteri were stained using the Salewski technique in order to detect any former implantation sites and the number of corpora lutea was recorded in addition.
Organs (brain, cervix, epididymis, glands (adrenal, coagulation, parathyroid, prostate, seminal vesicle and thyroid), heart, kidney, liver, ovaries, spleen, testes, thymus and uterus) were weighed at necropsy for all animals at scheduled euthanasia. Organ weights were not recorded for animals found dead. Paired organs were weighed together. Organ to body weight ratios (using the terminal body weight) were calculated.
Histopathological examination of all major tissues as defined in the OECD guidelines was performed for 5 animals/sex in the control and high dose groups and for animals found dead. In addition the liver of 5 animals (both sexes) in the low and the mid dose groups were histopathologically examined, based on possible treatment-related changes in this tissue.
For males that failed to sire (except for males which were selected) and females that failed to deliver pups the reproductive tissues (cervix, epididymis, coagulation gland, prostate gland, seminal vesicles, ovaries, testes, uterus and vagina) were histopathologically examined.
All gross lesions/masses found were histopathologically examined.
For the testes of 5 males of the control and the high dose group and for all males that failed to sire, a detailed qualitative examination was made, taking into account the tubular stages of the spermatogenic cycle. - Statistics:
- All statistical tests were conducted at the 5% significance level. All pairwise comparisons were conducted using two sided tests and were reported at the 1% or 5% levels.
Numerical data collected on scheduled occasions for the listed variables were analyzed as indicated according to sex and occasion. Descriptive statistics number, mean and standard deviation (or %CV or SE when deemed appropriate) were reported whenever possible. Inferential statistics were performed according to the matrix below when possible, but excluded semi-quantitative data, and any group with less than 3 observations.
The following pairwise comparisons were made:
Low dose group vs. control group, mid dose group vs. control group, high dose group vs. control group.
Datasets with at least 3 groups (the designated control group and 2 other groups) were compared using Dunnett-test (many-to-one-t-test).
For the motor activity data set (at least 3 groups) parametric (ANOVA) tests on group means were applied with Bonferroni correction for multiple testing. Mixed modelling techniques, comparing six different covariance structures, were used in order to select the best fitting statistical model.
Datasets with at least 3 groups was compared using a Steel-test (many-to-one rank test).
An overall Fisher’s exact test was used to compare all groups at the 5% significance level. The above pairwise comparisons were conducted using Fisher’s exact test whenever the overall test is significant.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- - See Table 1.1 (Page 44-45) of the attached full study report -
No adverse treatment related clinical signs were noted during daily detailed clinical observations. No findings were noted during the weekly arena observations in this study.
Five females at 120 mg/kg bw/day showed piloerection on Day 5 of dosing. This clinical sign was considered treatment related, but as it occurred on a single day of treatment only it was regarded non-adverse.
Salivation seen after dosing among all animals of the 30, 60 and 120 mg/kg bw/day dose groups starting on Day 5 of the treatment period (and in one control female on Day 12 of treatment) was considered not toxicologically relevant, taking into account the nature and mainly minor severity of the effect and its time of occurrence (i.e. after dosing). This sign was considered to be a physiological response rather than a sign of systemic toxicity.
Any other clinical signs noted during the treatment period occurred within the range of background findings to be expected for rats of this age and strain which are housed and treated under the conditions in this study and did not show any apparent dose-related trend. At the incidence observed, these were considered to be unrelated to treatment. - Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- No mortality occurred during the study period that was considered to be related to treatment with the test item.
One female at 30 mg/kg bw/day was found dead on Day 7 post coitum. No clinical signs were observed that were associated with its death. At necropsy beginning autolysis, a soft urinary bladder wall (probably a result of autolysis) and many dark red foci on the thymus were recorded. There were no microscopic observations indicating the cause of death. At the isolated incidence observed and with the absence of a dose related trend, this death was considered an incidental occurrence rather than related to treatment with the test item. - Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- - See Table 1.2 and 1.3 (Page 46-49) of the attached full study report -
Body weights and body weight gain were considered to have been unaffected by treatment with the test item up to 120 mg/kg bw/day.
For males, any statistical significances compared with the control group were considered not treatment related, as this was caused by relatively high control values. Males of all treated groups showed a comparable body weight gain within the normal range.
In the absence of a dose related trend no toxicological relevance was attached to the statistically significantly increased absolute body weight in females at 30 mg/kg bw/day on Day 8 of pre-mating. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- - See Table 1.4 and 1.5 (Page 50-53) of the attached full study report -
Food consumption before or after correction for body weight was considered unaffected by treatment with the test item up to 120 mg/kg bw/day.
A trend was observed towards decreased food consumption in females of all treatment groups during lactation and on Days 7-14 post-coitum at 120 mg/kg bw/day. As changes compared to the concurrent control group were relatively slight (reaching no statistical significance) no toxicological significance was attached to this finding. - Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- - See Table 1.8 (Page 63-66) of the attached full study report -
Decreased reticulocyte counts were found in males at 120 mg/kg bw/day (0.84x of control). As mean values remained within the historical control range this change was considered not toxicologically relevant.
Historical control data for Wistar Han rats; F0-animals (period 2017-2019):
Reticulocytes (109/L) – males: mean = 220.7; P5 – P95 = 163.70-289.20 (n=331).
Coagulation parameters of treated rats were considered not to have been affected by treatment. The increased mean prothrombin time (PT) in males at 120 mg/kg bw/day was caused by one individual. As mean values were within the historical control range and individual values (except for the male mentioned before) were within the same range as control, this change was considered not toxicologically relevant. In the absence of a dose related trend, decreased activated partial thromboplastin time (APTT) in males at 60 mg/kg bw/day was considered not related to treatment with the test item. - Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- - See Table 1.9 (Page 67-70) of the attached full study report -
Decreased total protein concentrations were found in males starting at 60 mg/kg bw/day and in females starting at 30 mg/kg bw/day (up to 0.90x and 0.93x of control for males and females, respectively, not statistically significant for females at 60 mg/kg bw/day). Mean values were below or on the lower limit of the historical control range. In males, this change was considered test item related. In the absence of a dose related trend, in females these changes were regarded not related to treatment with the test item.
Decreased albumin concentrations were measured in males starting at 60 mg/kg bw/day and in females starting at 30 mg/kg bw/day (up to 0.95x and 0.91x of control in males and females, respectively, not statistically significant for females at 60 mg/kg bw/day). As mean values remained within the historical control range (both sexes) and no dose related trend was observed (females) these changes were considered not toxicologically relevant.
Decreased cholesterol levels were found in males starting at 60 mg/kg bw/day (up to 0.76x of control, statistically significant in the high dose only). As mean values remained within the historical control range this change was considered not toxicologically relevant.
Decreased calcium levels in males were measured starting at 60 mg/kg bw/day (0.94x of control). As mean values remained within the historical control range and in the absence of a dose related trend, this change was considered not toxicologically relevant.
The change in glucose in males at 30 mg/kg bw/day was considered not related to treatment with the test item as it occurred in the absence of a dose-related trend.
Historical control data for Wistar Han rats; F0-animals (period 2017-2019):
Total protein (g/L) – males: mean = 64.2; P5 – P95 = 60.60-67.90 (n=355).
Total protein (g/L) – females: mean = 57.8; P5 – P95 = 52.80-67.90 (n=325).
Albumin (g/L) – males: mean = 32.4; P5 – P95 = 30.60-34.40 (n=355).
Albumin (g/L) – females: mean = 30.3; P5 – P95 = 27.40-36.60 (n=325).
Cholesterol (mmol/L) – males: mean = 1.95; P5 – P95 = 1.390-2.550 (n=355).
Calcium (mmol/L) – males: mean = 2.62; P5 – P95 = 2.490-2.750 (n=355).
Serum levels of total T4 in males were considered unaffected by treatment with the test item up to 120 mg/kg bw/day. Assessment of T4 (females) and Thyroid Stimulating Hormone (TSH; both sexes) was considered not relevant because no treatment-related changes in T4 were noted in the males, furthermore no adverse effects on thyroid histopathology and no treatment related changes in thyroid weight were recorded. - Behaviour (functional findings):
- effects observed, treatment-related
- Description (incidence and severity):
- - See Table 1.6 and 1.7 (Page 54-62) of the attached full study report -
Functional observation parameters were considered unaffected by treatment in males up to 60 mg/kg bw/day and in females up to 120 mg/kg bw/day. In males at 120 mg/kg bw/day grip strength of the hind leg was decreased (0.80x of control). This change was considered test item related.
Hearing ability, pupillary reflex and static righting reflex were normal in all examined animals up to 120 mg/kg bw/day.
Decreased total movements and ambulations in males starting at 30 mg/kg bw/day, as well as increased total movements and ambulations in females starting at 30 mg/kg bw/day were considered the result of relatively high or low control values. All groups showed a similar motor activity habituation profile with a decreasing trend in activity over the duration of the test period, no difference in activity between control and treated animals was observed during daily clinical observations or weekly arena observations, and no dose-related trend was observed. Altogether, the differences observed in total movements and ambulations were considered not related to treatment with the test item. - Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- - See Table 1.11 (Page 73-76) of the attached full study report -
Test item-related higher liver weights (absolute and/or relative to body weights) were noted in males and females. For males and females, the effect on liver weight at 120 mg/kg bw/day were considered test item related. For males, the higher liver weights at 30 and 60 mg/kg bw/day were without a dose response and in absence of any microscopic findings and were therefore considered unlikely to be test item related.
Decreased absolute and relative spleen weight in females starting at 30 mg/kg bw/day (statistically significant on some occasions) was considered the result of relatively high control values and in the absence of a dose related trend or microscopic findings regarded not related to treatment with the test item.
Statistically significantly increased seminal vesicle weight (relative to body weight) in males at 120 mg/kg bw/day were considered the result of relatively low control values and in the absence of microscopic findings were regarded not related to treatment with the test item.
Statistically significantly increased absolute ovary weight in females at 30 mg/kg bw/day (1.27x of control, no significant difference was recorded for relative ovary weight) was considered not treatment related in the absence of a dose related trend.
Historical control data for Wistar Han rats; F0-animals (period 2017-2019):
Seminal vesicles (%) – males: mean = 0.384; P5 – P95 = 0.2780-0.4947 (n=737).
Spleen (g) – females: mean = 0.496; P5 – P95 = 0.3980-0.6030 (n=310).
Spleen (%) – females: mean = 0.176; P5 – P95 = 0.1445-0.2114 (n=310). - Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- - See Table 1.10 (Page 71-72) of the attached full study report -
Test item-related enlarged liver was observed in a single female at 120 mg/kg bw/day. This correlated with higher liver weight and hepatocellular hypertrophy. The foci recorded on the glandular mucosa of the stomach in two males at 120 mg/kg bw/day were considered not toxicologically relevant in absence of correlating microscopic findings.
The remainder of the recorded macroscopic findings were within the range of background gross observations encountered in rats of this age and strain. - Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- - See Appendix 4 (Page 191-297 of the attached full study report -
Test item and dose related microscopic findings after treatment with the test item were noted in the liver of males and females.
Hepatocellular hypertrophy (mainly periportal) was present in the liver of females treated at 60 mg/kg bw/day (minimal degree), and in males (minimal degree) and females (up to slight degree) at 120 mg/kg bw/day.
For one female at 120 mg/kg bw/day hepatocellular hypertrophy correlated with higher liver weight and with macroscopically enlarged liver.
The remainder of the recorded microscopic findings were within the range of background pathology encountered in rats of this age and strain. There was no test item related alteration in the prevalence, severity, or histologic character of those incidental tissue alterations. - Other effects:
- no effects observed
- Description (incidence and severity):
- Length and regularity of the estrous cycle were considered not to have been affected by
treatment. - Details on results:
- - See Table 1.12 (Page 77) of the attached full study report -
There were 2/10 couples treated at 60 mg/kg/day and 5/10 couples at 120 mg/kg/day that were not pregnant. In addition, there was one female at 60 mg/kg/day with one late resorption only. Histopathology did not reveal any changes in the reproductive organs that could explain this high incidence in reproductive failure. Stage dependent qualitative evaluation of spermatogenesis in the testis was performed. The testes revealed normal progression of the spermatogenic cycle, and the expected cell associations and proportions in the various stages of spermatogenesis were present. The males that did not fertilize the females also showed normal spermatogenesis.
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 120 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects observed up to and including the highest dose tested.
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- Under the conditions of the test (OECD 422, GLP), the systemic NOAEL was determined to be at least 120 mg/kg bw/day.
- Executive summary:
Introduction and method: The substance was tested in a Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test (OECD 422) following GLP. The dose levels in this study were selected to be 0, 30, 60, 120 mg/kg/day, based on the results of the dose range finder in which mortality was observed at 450 mg/kg/day but no severe effects were recorded at 90 mg/kg/day. The test item and vehicle (water) were administered once daily by oral gavage 7 days a week for a minimum of 29 days. Males were treated for 29 days, up to and including the day before scheduled necropsy. This included a minimum of 14 days prior to mating and during the mating period. Females that delivered were treated for 50 to 57 days, i.e. 14 days prior to mating (with the objective to cover at least two complete estrous cycles), the variable time to conception, the duration of pregnancy and at least 13 days after delivery, up to and including the day before scheduled necropsy.
Parameters measured: Mortality/moribundity, clinical signs, functional observations, body weight and food consumption, estrous cycle determination, clinical pathology, measurement of thyroid hormone T4 (F0-males), gross necropsy findings, organ weights and histopathologic examinations. In addition, the following reproduction/developmental parameters were determined: mating and fertility indices, precoital time, number of implantation sites, gestation index and duration, parturition, maternal care, sex ratio and early postnatal pup development (mortality, clinical signs, body weights, sex, anogenital distance, areola/nipple retention and macroscopy, measurement of thyroid hormone T4 (PND 14-16 pups)).
Results: Mortality: One female (No. 52) at 30 mg/kg/day was found dead on Day 7 post-coitum. No clinical signs were observed that were associated with its death. At necropsy beginning autolysis, a soft urinary bladder wall (probably a result of autolysis) and many dark red foci on the thymus were recorded. There were no microscopic observations indicating the cause of death. At the isolated incidence observed and with the absence of a dose-related trend, this death was considered an incidental occurrence rather than related to treatment with the test item.
Clinical signs: No toxicologically significant changes were noted.
Functional observation tests: No toxicologically significant changes were noted.
Body weight: No toxicologically significant changes were noted.
Food consumption: No toxicologically significant changes were noted.
Haematology and clotting parameters: No effects observed.
Clinical chemistry: Decreased total protein concentrations in males starting at 60 mg/kg/day were considered non-adverse in the absence of corroborating findings.
Hormone levels: Male T4 thyroid hormone levels were not affected.
Organ weights and histopathology: Relationships were suspected between enlarged liver, increased liver weight and hepatocellular hypertrophy. The (mainly periportal) hepatocellular hypertrophy in females at 60 and 120 mg/kg/day and males at 120 mg/kg/day was considered non-adverse at the current severities (minimal to slight) and in the absence of any degenerative findings. Therefore, the higher liver weights (up to 19%) in males and females were considered non-adverse.
Conclusion: In conclusion, based on the results of this combined 28-day repeated dose toxicity study with the reproduction/developmental toxicity screening test, the parental NOAEL is at least 120 mg/kg/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.